2/2
© Reuters. FILE PHOTO: Allergan CEO Brent Saunders gives an interview on the floor of the New York Stock Exchange (NYSE) April 6, 2016. REUTERS/Brendan McDermid/
2/2
© Reuters. FILE PHOTO: Allergan CEO Brent Saunders gives an interview on the floor of the New York Stock Exchange (NYSE) April 6, 2016. REUTERS/Brendan McDermid/
2/2
(Reuters) -Eye-care company Bausch + Lomb Corp is expected to name Saunders, the former chief executive of Allergan (NYSE:), as its CEO and chairman of board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
The leadership change could be announced as soon as Wednesday, according to the report.
Bausch + Lomb is in the process of being spun out from Bausch Health Companies (NYSE:), which was formerly known as Valeant.
Brent Saunders served as the CEO of Allergan until it was bought out by AbbVie Inc (NYSE:) for $63 billion in 2020.
Bausch + Lomb did not immediately respond to a Reuters request for comment.
Be the first to comment